Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Olanzapine in an atypical antipsychotic agent which is associated with significant weight gain. • Metformin, an anti‐hyperglycaemic agent, has been used to treat or prevent weight gain associated with olanzapine. • Meta‐analyses on studies that have examined the use of metformin for treatment of antipsychotic‐induced weight gain report significant heterogeneity. WHAT THIS STUDY ADDS • Systematic review and meta‐analysis showed that metformin is useful for the short‐term treatment of olanzapine‐induced weight gain. Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome. A variety of pharmacological agents has been studied in the efforts to reverse weight gain induced by olanzapine, but current evidence is insufficient to support any particular pharmacological approach. We conducted a systematic review and meta‐analysis of randomized controlled trials of metformin for the treatment of olanzapine‐induced weight gain. Systematic review of the literature revealed 12 studies that had assessed metformin for antipsychotic‐induced weight gain. Of these, four studies (n= 105) met the review inclusion criteria and were included in the final analysis. Meta‐analysis was performed to see the effect size of the treatment on body weight, waist circumference and body‐mass index (BMI). Weighted mean difference (WMD) for body…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 105 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.